BiotechTube

LAS 41002 + Active

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Eczema

Conditions

Atopic Eczema

Trial Timeline

Feb 1, 2010 → Mar 1, 2010

NCT ID
NCT01119313

About LAS 41002 + Active

LAS 41002 + Active is a phase 2 stage product being developed by Almirall for Atopic Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT01119313. Target conditions include Atopic Eczema.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01119313Phase 2Completed

Competing Products

20 competing products in Atopic Eczema

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52

Other Products from Almirall

TildrakizumabApproved
80
Tiotropium + AclidiniumApproved
80
Dimethyl fumarate (DMF) standard scheme + Dimethyl fumarate (DMF) simplified scheme + TildrakizumabApproved
80
Pidotimod + PlaceboApproved
80
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelApproved
80